Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma



Downloads per month over past year

Andrés Guerrero, Vanessa and Perucho González, Lucía and García Feijoo, Julián and Morales Fernández, Laura and Sáenz Francés, Federico and Herrero Vanrell, Rocío and Pablo Júlvez, Luis and Polo Llorens, Vicente and Martínez de la Casa, Jose Maria and Konstas, Anastasios Georgios P. (2017) Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma. Advances in Therapy, 34 (2). pp. 378-395. ISSN 0741-238X

[thumbnail of use anti-VEGF-advancestherap-2017.pdf]
Creative Commons Attribution Non-commercial.


Official URL:


The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.

Item Type:Article
Additional Information:

Received: October 17, 2016 / Published online: December 20, 2016.
To view enhanced content for this article go to:

Uncontrolled Keywords:Angiogénesis ; Aflibercept ; Bevacizumab ; Glaucoma filtration surgery ; Neovascular glaucoma ; Ranibizumab, VEGF, Wound modulation
Subjects:Medical sciences > Medicine > Ophtalmology
Medical sciences > Pharmacy > Drugs
ID Code:44600
Deposited On:14 Sep 2017 12:48
Last Modified:04 Nov 2020 11:01

Origin of downloads

Repository Staff Only: item control page